Vicore Pharma Completes Enrollment in the Phase 2b ASPIRE Trial of Buloxibutid in Idiopathic Pulmonary Fibrosis
The original release is unavailable here.
Earlier from Vicore Pharma Holding Ab
- Notice Of Annual General Meeting In Vicore Pharma Holding AB (PUBL)
- Vicore Publishes the Annual Report for 2025
- Vicore Pharma to Present at Upcoming Investor Conferences
- Vicore Pharma Elevates Leadership Team Ahead of Key Clinical and Corporate Milestones